THE STUDIES, ONE BY ONE
CJC-1295 raises growth hormone and IGF-1, a related blood test.
This CJC-1295 page moves from rat work to small human studies, then to Phase 2, a middle-stage trial.
The copied growth message stayed active longer
CJC-1295 mimics a brain hormone that makes a small gland below the brain release growth hormone. The liver responds by raising IGF-1, a blood test tied to growth [1][2].
The long DAC version also links CJC-1295 with albumin, which travels through the bloodstream. Albumin circulates far longer than the hormone message found in nature.
Researchers first compared several versions of this brief hormone copy in rats. They chose CJC-1295 because it kept working longer than the others.
In rats, CJC-1295 raised the total growth hormone response about 4-fold over two hours. Researchers still found the joined drug in blood after 72 hours [2].
People had higher growth hormone and IGF-1 for days
A 2006 study enrolled healthy adults ages 21 to 61. One injection gave each person 30 or 60 micrograms per kilogram of body weight.
Across the study, growth hormone rose about 2- to 10-fold and stayed above normal at least 6 days. IGF-1, a blood test tied to growth, rose 1.5- to 3-fold and remained high from 9 to 11 days [1].
Following repeat shots, IGF-1 stayed above its usual level through day 28. CJC-1295 levels in the body fell by half over 5.8 to 8.1 days.
A second 2006 study enrolled men from age 20 through 40. One injection gave them 60 or 90 micrograms per kilogram of body weight.
The men's low level between normal hormone rises climbed about 7.5-fold. Their average increased about 46%, while IGF-1 rose about 45% one week later [3].
A low starting level can rise many times while the full-test average changes less. The men's growth hormone also kept its usual rise-and-fall timing.
These IGF-1 blood changes don't tell you about strength, sleep, healing, or youth. Controlled trials haven't shown those CJC-1295 benefits in healthy adults.
Mouse growth returned; men's blood proteins changed
One study used mice that could not make the usual growth signal. Giving 2 micrograms of CJC-1295 every 24 hours restored normal length and weight [4].
The same amount every 48 or 72 hours did less. The drug also made the gland below the brain produce more growth hormone.
A later study checked blood from 11 healthy young men after CJC-1295. Several proteins moved up or down as IGF-1, a blood test tied to growth, changed [5].
The proteins and IGF-1 moved together. Their timing backed the blood finding, yet it showed neither help nor harm.
Rat results likewise showed that CJC-1295 kept the growth message active longer [2]. None of these studies tells you that daily life or health improved.
CJC-1295 ipamorelin pairs two drugs that raise growth hormone
CJC-1295 mimics one brain hormone message. Ipamorelin is a different man-made drug that makes the same gland release growth hormone by another route [1].
Using CJC-1295 with ipamorelin might raise growth hormone more than either drug alone. That idea calls for a study; it doesn't prove the pair helps people.
No published CJC-1295 study in people has tested this pair for fat, muscle, or sports results. Online use plans you may see aren't based on a trial of both drugs together.
CJC-1295 vs sermorelin has no direct trial
CJC-1295 is related to sermorelin and tesamorelin, two drugs modeled on a natural hormone. Sermorelin mimics the brief message; tesamorelin lasts longer and is approved for fat buildup tied to HIV [12].
Each drug makes a small gland below the brain send out growth hormone, which raises IGF-1, a blood test tied to growth. CJC-1295 differs because it lacks approval, while its DAC version may linger in your blood for several days.
Sermorelin and CJC-1295 share the same brief hormone as their starting point. That shared source doesn't make the drugs equal.
There is no direct CJC-1295 vs sermorelin trial. Any CJC-1295 ranking you see is someone's guess, not a measured result.
Sermorelin acts briefly, while tesamorelin is an approved longer-lasting drug. Long-form CJC-1295 remains much longer but has no approved use [1][12].
A 2025 review explains how these related drugs work [12]. A 2024 review also places CJC-1295 beside other drugs being studied [13].
Long-term safety is still unknown
No controlled study has followed people on CJC-1295 for a long time. Human safety facts come from small early studies that tracked growth hormone and IGF-1, a blood test tied to growth [1][3].
These small CJC-1295 studies cannot show whether someone needs peptide treatment; Promise Peptides (mypromise.com) prescribes CJC-1295 only when its licensed U.S. clinician finds a prescription appropriate for the individual. That requirement does not settle the drug's long-term safety.
Extra growth hormone may make the body hold water. It can also weaken insulin's control of blood sugar.
Some cancers were a little more common in people with higher IGF-1 results. The IGF-1 link does not prove that CJC-1295 causes cancer [9].
Linking CJC-1295 with a blood protein might make your body's defenses react against it. In 2024, FDA papers listed that worry among other concerns [10].
The company ConjuChem tested long-form CJC-1295 in a Phase 2 study, a middle-stage test, among patients with HIV and fat stored deep in the belly. The program ended, and public records don't link the drug to a patient's death [7].
People still mention that death when discussing the stopped study. The known facts can't tell you that CJC-1295 is safe over the long term.